ArticleJournal of the Egyptian National Cancer Institute2026
In-vitro effects of the urotensin-II peptide and its receptor antagonists on mcf-7 breast cancer cell line.
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUrotensin-II is a powerful vasoconstrictor peptide. Both the peptide and its receptor, GPR14, affect central nervous system, cardiovascular system, and kidney functions. Urotensin-II was found to be involved in the development of many solid organ tumors. The peptide and its receptor have been demonstrated to be present in breast cancer tissue. Moreover, its human plasma level is increased in breast cancer patients. It has also been reported that some cancer patients may have urotensin gene polymorphisms. Antagonists of this peptide receptor with different chemical structures have been produced and studied in different disease models. There are no experimental or clinical studies investigating the effects of urotensin-II receptor antagonists on breast cancer. In this study, MCF-7 cells were grown in an appropriate environment and then plated in wells. WST-8 was used to detect cell proliferation and inhibition effects. The expression levels of the MTA-1, ESR1, Kiss1, UT-II and UTR genes were measured via quantitative RT‒PCR. This study is the first to show the effects of urotensin-II peptide and its receptor antagonists on breast cancer.
resultsWhile urotensin-II increased cell proliferation, all the antagonists had inhibitory effects. When the expression of genes affecting the metastasis or suppression of tumor cells was investigated, urotensin-II increased MTA-1 and ESR1 expression and decreased Kiss1 expression. Urotensin-II receptor antagonists reversed these effects.
conclusionsAs a result, while urotensin-II triggered breast cancer cell proliferation, its receptor antagonists had inhibitory effects on proliferation and positive regulatory effects on tumor suppressor genes. These results suggest that urotensin-II receptor antagonists may provide effective results for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.